Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Negar N. Alami"'
Autor:
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Publikováno v:
Pharmacology Research & Perspectives, Vol 11, Iss 1, Pp n/a-n/a (2023)
Abstract ABBV‐47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS‐CoV‐2. This first‐in‐human safety, pharmacokinetics, and antiviral pharmacodynamic as
Externí odkaz:
https://doaj.org/article/1ec46728fbc04f62a659f561489d4b07
Autor:
Farida Ismail Al Hosani, Kimberly Pringle, Mariam Al Mulla, Lindsay Kim, Huong T. Pham, Negar N. Alami, Ahmed Khudhair, Aron J. Hall, Bashir Aden, Feda El Saleh, Wafa Al Dhaheri, Zyad Al Bandar, Sudhir Bunga, Kheir Abou Elkheir, Ying Tao, Jennifer C. Hunter, Duc T. Nguyen, Andrew Turner, Krishna Pradeep, Jurgen Sasse, Stefan Weber, Suxiang Tong, Brett L. Whitaker, Lia M. Haynes, Aaron Curns, Susan I. Gerber
Publikováno v:
Emerging Infectious Diseases, Vol 22, Iss 7, Pp 1162-1168 (2016)
In January 2013, several months after Middle East respiratory syndrome coronavirus (MERS-CoV) was first identified in Saudi Arabia, Abu Dhabi, United Arab Emirates, began surveillance for MERS-CoV. We analyzed medical chart and laboratory data collec
Externí odkaz:
https://doaj.org/article/531b5a89634c46faa69586e92591f8a4
Autor:
Jennifer C. Hunter, Duc T. Nguyen, Bashir Aden, Zyad Al Bandar, Wafa Al Dhaheri, Kheir Abu Elkheir, Ahmed Khudair, Mariam Al Mulla, Feda El Saleh, Hala Imambaccus, Nawal Al Kaabi, Farrukh Amin Sheikh, Jurgen Sasse, Andrew Turner, Laila Abdel Wareth, Stefan Weber, Asma Al Ameri, Wesal Abu Amer, Negar N. Alami, Sudhir Bunga, Lia M. Haynes, Aron J. Hall, Alexander J. Kallen, David T. Kuhar, Huong T. Pham, Kimberly Pringle, Suxiang Tong, Brett L. Whitaker, Susan I. Gerber, Farida Ismail Al Hosani
Publikováno v:
Emerging Infectious Diseases, Vol 22, Iss 4, Pp 647-656 (2016)
Middle East respiratory syndrome coronavirus (MERS-CoV) infections sharply increased in the Arabian Peninsula during spring 2014. In Abu Dhabi, United Arab Emirates, these infections occurred primarily among healthcare workers and patients. To identi
Externí odkaz:
https://doaj.org/article/8952cd33250f4aa18820e67666efdf11
Autor:
Mohamad Shebley, Stanley Wang, Izna Ali, Preethi Krishnan, Rakesh Tripathi, Joseph M. Reardon, John Cafardi, Galia Rahav, Yoseph Caraco, Jihad Slim, Fadi Al Akhrass, Mengjia Yu, Yiran Hu, Rosa De Abreu Ferreira, Negar N. Alami
Publikováno v:
Pharmacology Research & Perspectives. 11
Autor:
Mohamad, Shebley, Stanley, Wang, Izna, Ali, Preethi, Krishnan, Rakesh, Tripathi, Joseph M, Reardon, John, Cafardi, Galia, Rahav, Yoseph, Caraco, Jihad, Slim, Fadi, Al Akhrass, Mengjia, Yu, Yiran, Hu, Rosa De Abreu, Ferreira, Negar N, Alami
Publikováno v:
Pharmacology researchperspectivesREFERENCES. 11(1)
ABBV-47D11 is a neutralizing monoclonal antibody that targets a mutationally conserved hydrophobic pocket distal to the ACE2 binding site of SARS-CoV-2. This first-in-human safety, pharmacokinetics, and antiviral pharmacodynamic assessment in patient
Autor:
Steven E Coutre, Christopher Barnett, Olayemi Osiyemi, Daanish Hoda, Moti Ramgopal, Alexander C Fort, Roula Qaqish, Yiran Hu, Joi Ninomoto, Negar N Alami, Lori Styles, Steven P Treon
Publikováno v:
Open forum infectious diseases. 9(5)
Background Few therapies are approved for hospitalized patients with severe coronavirus disease 2019 (COVID-19). Ibrutinib, a once-daily Bruton tyrosine kinase inhibitor, may mitigate COVID-19–induced lung damage by reducing inflammatory cytokines.
Autor:
Kwang Hyub Han, Si Hyun Bae, Eric Crown, Yoon Jun Kim, Ki Tae Yoon, Ji Hoon Kim, Seung Woon Paik, Dohyun Kim, Armen Asatryan, Jin-Woo Lee, Mong Cho, Negar N. Alami, Jeong Heo, Linda M Fredrick, Sook-Hyang Jeong, Young-Suk Lim, Youn-Jae Lee
Publikováno v:
Gut and Liver
Background/aims Glecaprevir/pibrentasvir (G/P) is the first pan-genotypic direct-acting antiviral combination therapy approved in Korea. An integrated analysis of five phase II and III trials was conducted to evaluate the efficacy and safety of G/P i
Autor:
Margaret Burroughs, Preethi Krishnan, N. Mobashery, Armen Asatryan, Wenjing Lu, Negar N. Alami, Qing Xie, Mingxiang Zhang, Wen Xie, Guiqiang Wang, Lai Wei, Jeong Heo, Jidong Jia, Hari V. Kalluri, Rakesh Tripathi, Seng Gee Lim, Jinlin Hou, Wei Liu, Linda M Fredrick, Yoon Jun Kim
Publikováno v:
SSRN Electronic Journal.
Background: Glecaprevir/pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data in non-Japanese Asian patients have been minimal. Methods: Two phase 3 studies
Autor:
Seng Gee Lim, N. Mobashery, Wei Liu, Yoon Jun Kim, Jidong Jia, Mingxiang Zhang, Jinlin Hou, Wenjing Lu, Lai Wei, Margaret Burroughs, Guiqiang Wang, Negar N. Alami, Rakesh Tripathi, Preethi Krishnan, Jeong Heo, Armen Asatryan, Linda M Fredrick, Qing Xie, Wen Xie, Hari V. Kalluri
Publikováno v:
The lancet. Gastroenterologyhepatology. 5(9)
Glecaprevir-pibrentasvir results in high rates of sustained virological response in patients with chronic hepatitis C virus (HCV) genotype 1-6 infection. Data for glecaprevir-pibrentasvir in non-Japanese Asian patients have been minimal. The aim of t
Autor:
Gamal Esmat, Reham Soliman, Naglaa Allam, N. Mobashery, Mohamed Hassany, Gamal Shiha, Sarah Kopecky-Bromberg, Negar N. Alami, Mohammad A. Mohey, Coleen Hall, Rabab Fouad, Roula B. Qaqish, Imam Waked
Publikováno v:
Journal of Medical Virology
In AGATE‐II, treatment with ombitasvir coformulated with paritaprevir/ritonavir plus ribavirin (RBV) in Egyptians infected with hepatitis C virus genotype 4 resulted in high rates of sustained virologic response at post‐treatment week 12. This su